135 related articles for article (PubMed ID: 8915932)
1. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1.
Lassiter HA; Robinson TW; Brown MS; Hall DC; Hill HR; Christensen RD
J Perinatol; 1996; 16(5):346-51. PubMed ID: 8915932
[TBL] [Abstract][Full Text] [Related]
2. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
Lassiter HA; Speranza MJ; Hall RT; Meade V; Christensen RD; Parker CJ
J Perinatol; 1990 Mar; 10(1):27-31. PubMed ID: 2107285
[TBL] [Abstract][Full Text] [Related]
3. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
4. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G.
Sandberg K; Fasth A; Berger A; Eibl M; Isacson K; Lischka A; Pollak A; Tessin I; Thiringer K
J Pediatr; 2000 Nov; 137(5):623-8. PubMed ID: 11060526
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates.
Christensen RD; Hardman T; Thornton J; Hill HR
J Perinatol; 1989 Jun; 9(2):126-30. PubMed ID: 2738720
[TBL] [Abstract][Full Text] [Related]
6. [Serum levels of IgG subclasses in critically ill premature infants treated with intravenous immunoglobulins].
Puccio VF; Soliani M; Corea D; Puncuh F; Massone ML; Nahum L; Pisano F; Castellani R; Cornaglia-Ferraris P
Minerva Pediatr; 1991 Oct; 43(10):637-44. PubMed ID: 1758385
[TBL] [Abstract][Full Text] [Related]
7. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin for sepsis prevention in preterm infants.
Tanzer F; Yazar N; Hakgüdener Y; Kafali G
Turk J Pediatr; 1997; 39(3):341-5. PubMed ID: 9339113
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
Basta M; Kirshbom P; Frank MM; Fries LF
J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
[TBL] [Abstract][Full Text] [Related]
10. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli.
Lassiter HA; Wilson JL; Feldhoff RC; Hoffpauir JM; Klueber KM
Pediatr Res; 1994 Apr; 35(4 Pt 1):389-96. PubMed ID: 8047374
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous immunoglobulin on opsonic activity and TNF production in patients at high risk for sepsis syndrome.
Nazzari C; Gaeta A; Lun MT; Raponi G; Antonelli M; Mancini C; Filadoro F
New Microbiol; 1993 Jul; 16(3):251-8. PubMed ID: 8366821
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis.
Shenoi A; Nagesh NK; Maiya PP; Bhat SR; Subba Rao SD
Indian Pediatr; 1999 Nov; 36(11):1113-8. PubMed ID: 10745332
[TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin.
Benjamin DK; Schelonka R; White R; Holley HP; Bifano E; Cummings J; Adcock K; Kaufman D; Puppala B; Riedel P; Hall B; White J; Cotton CM;
J Perinatol; 2006 May; 26(5):290-5. PubMed ID: 16598296
[TBL] [Abstract][Full Text] [Related]
14. [Effect of intravenous human immunoglobulins on bacterial clearance and mortality in experimental Escherichia coli K 1 septicemia in chicken].
Labarthe JC; Guillot JF; Mouline C; Brée A
Pathol Biol (Paris); 1991 Mar; 39(3):177-81. PubMed ID: 2052419
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin in the prevention and treatment of neonatal bacterial sepsis.
Lassiter HA
Adv Pediatr; 1992; 39():71-99. PubMed ID: 1442320
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
Darenberg J; Ihendyane N; Sjölin J; Aufwerber E; Haidl S; Follin P; Andersson J; Norrby-Teglund A;
Clin Infect Dis; 2003 Aug; 37(3):333-40. PubMed ID: 12884156
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immune globulin therapy for early-onset sepsis in premature neonates.
Weisman LE; Stoll BJ; Kueser TJ; Rubio TT; Frank CG; Heiman HS; Subramanian KN; Hankins CT; Anthony BF; Cruess DF
J Pediatr; 1992 Sep; 121(3):434-43. PubMed ID: 1517923
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Muscle Nerve; 2005 Apr; 31(4):487-94. PubMed ID: 15685615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
